share_log

Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'

Benzinga ·  May 15 21:07

On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said under $30, Pfizer Inc. (NYSE:PFE) is a gift.

Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform under the brand "Pfizer for All."

Jim Lebenthal of Cerity Partners said QUALCOMM Incorporated (NASDAQ:QCOM) is breaking out right now.

On May 14, Qualcomm and Aramco reported a collaboration that includes accelerating development of industrial 4G/5G NGN ecosystem.

Don't forget to check out our premarket coverage here

Sarat Sethi of DCLA said Freeport-McMoRan Inc. (NYSE:FCX) is a copper play, and demand for copper is going through the roof.

On April 23, Freeport said first-quarter revenue stood at $6.32 billion, beating the consensus of $5.66 billion. Adjusted EPS was 32 cents, beating the consensus of 27 cents.

Amy Raskin of Chevy Chase Trust named Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as her final trade.

On May 6, Vertex Pharmaceuticals posted stronger-than-expected results for its first quarter.

Price Action:

  • Pfizer shares fell 0.2% to close at $28.38 on Tuesday.
  • Qualcomm gained 2.6% to settle at $188.97 during Tuesday's session.
  • Freeport-McMoRan shares rose 2.8% to settle at $53.48 on Tuesday.
  • Vertex Pharmaceuticals shares slipped 0.3% to close at $428.59 on Tuesday.

Image: Shutterstock

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment